| Theme | An up-to-date review of the molecular-targeted therapies for inflammatory bowel disease | |
|---|---|---|
| Title | Review of consensus statement for the management of inflammatory bowel disease | |
| Publish Date | 2021/09 | |
| Author | Shiro Nakamura | 2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University |
| Author | Takako Miyazaki | 2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University |
| Author | Kazuki Kakimoto | 2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University |
| Author | Yuki Hirata | 2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University |
| Author | Naokuni Sakiyama | 2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University |
| Author | Ryoji Koshiba | 2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University |
| Author | Naohiko Kinoshita | 2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University |
| Author | Yuka Kawasaki | 2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University |
| Author | Keijiro Numa | 2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University |
| [ Summary ] | The Consensus Guidelines for the management of Inflammatory Bowel Disease were established and published by the Group for "Investigation and Research on Intractable Inflammatory Intestinal Disorders" (Hisamatsu Group, which includes Japanese specialists). These guidelines aim to optimize and standardize the treatment approaches to inflammatory bowel disease adopted by general physicians who treat this condition in routine practice. Following rapid advances in medical therapy in recent years, these guidelines are updated every year to provide the latest medical information and are widely adopted by medical personnel across Japan. This review describes the therapeutic principles and goals in patients with ulcerative colitis and Crohn's disease, as well as the indications and approaches to the selection of molecular targeted drugs that have been introduced in recent years, based on the latest consensus guideline-update released at the end of March 2021. | |